FDA staff are raising alarms about who actually has the authority to approve drugs under the Priority Review Voucher system. With vouchers now selling for up to $200 million and billions in rare disease investment hanging in the balance, the confusion couldn't come at a worse time.
Imagine buying a golden ticket worth $200 million, only to find out nobody's sure who runs the chocolate factory anymore.
That's roughly the situation facing biotech companies banking on FDA Priority Review Vouchers right now. Staff inside the agency have raised concerns about who actually has the legal authority to approve drugs under the voucher system, and the confusion couldn't come at a worse time. PRVs are deeply baked into how rare disease biotechs raise money, structure deals, and justify their entire existence. If the plumbing breaks, a lot of business models flood.
A Quick Primer on the Golden Tickets
Priority Review Vouchers work like this: develop a drug for a disease nobody else wants to touch (rare pediatric conditions, neglected tropical diseases, bioterror threats), and the FDA hands you a voucher when it approves your product. That voucher lets you, or anyone you sell it to, get a six-month review on a future drug instead of the standard ten months. Four extra months on the market for a blockbuster can be worth a fortune.
The concept came from a 2006 academic paper that pitched it as a "pull" incentive. Congress loved the idea and wrote it into law in 2007. Think of it like a loyalty reward: do something good for public health, get a fast pass you can use (or sell) later.
And sell they do. Jazz Pharmaceuticals sold a single voucher for $200 million in January 2026. That wasn't an outlier; it was the new floor. Bavarian Nordic sold one for $160 million. Abeona Therapeutics got $155 million. Recent scarcity has pushed prices into the $150 to $200 million range. These aren't rounding errors. For a small biotech, a PRV sale can fund years of research without diluting shareholders.
So Who's Running the Show?
The confusion centers on the Commissioner's National Priority Voucher pilot, a newer program layered on top of the older statutory PRV system. Under this pilot, a multidisciplinary "review council" discusses selected applications, but the actual approval decision supposedly still sits with the relevant FDA center (CDER for drugs, CBER for biologics). The operative word there is "supposedly."
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
FDA staff and outside observers have flagged that the program lacks clear statutory authorization. That means it could be vulnerable to legal challenge. There are also concerns that the ultra-fast one-to-two-month review timeline may not give reviewers enough time to properly evaluate safety and effectiveness. When your timeline is that aggressive, the question of who signs off isn't just procedural; it's about whether the science gets a fair hearing.
Meanwhile, the older Rare Pediatric Disease PRV program is on firmer legal ground. Congress recently reauthorized it through September 2029. But even that program has been a rollercoaster: it lapsed briefly in late 2024 when Congress initially failed to renew it, sending shockwaves through the rare disease world before legislators scrambled to extend it.
The Chaos Behind the Curtain
To understand why this procedural question matters so much, you need to zoom out and see the broader picture at the FDA. The agency is going through what can only be described as a leadership blender.
CDER, the center that reviews most drugs, has burned through five acting directors since early 2025. Tracy Beth Høeg was fired in May 2026. Richard Pazdur retired. George Tidmarsh resigned during a conduct probe. The center lost roughly 473 employees in fiscal year 2025 alone. CBER, which handles biologics and vaccines, lost about 224 staff in the same period and has had its own carousel of acting leaders.
The FDA doesn't even have a permanent commissioner right now. Marty Makary resigned in May 2026 after a clash over flavored e-cigarettes, and the acting commissioner is a lawyer, not a scientist. More than half of senior leaders from early 2025 had departed by late that year.
When you layer a novel voucher program with unclear legal authority on top of an agency in this much turmoil, you get a recipe for exactly the kind of confusion that's now surfacing. Career staff are doing the heavy lifting, but they're getting mixed signals about who has the final say, and the political appointees above them keep changing.
Why Wall Street Is Sweating
For biotech investors and dealmakers, PRVs aren't just nice-to-haves. They're load-bearing walls in valuation models.
A survey by the Rare Disease Company Coalition found that 85% of biotech executives said PRV potential materially influenced their decision to pursue rare pediatric programs. When the program briefly lapsed, 35% of companies reported canceling or delaying pipeline programs, and 50% expected greater difficulty raising capital. The coalition estimated roughly $4 billion in PRV value was at risk across about 200 rare disease therapies.
Analysts have responded by getting more cautious. Before 2024, many models treated PRVs as near-certain "found money" once a drug looked likely to qualify. Now, most sophisticated analysts break out three separate value layers: the base product value without any voucher, a probability-weighted PRV value (often discounted 50% or more for early-stage assets), and indirect benefits like earlier cash flows.
The uncertainty is also reshaping how deals get structured. Instead of baking PRV value into upfront payments, companies are increasingly using contingent milestones: a fixed payment when the voucher is actually awarded, plus a percentage of whatever the voucher sells for. Some contracts now include clauses that explicitly address what happens if Congress lets the program sunset again. It's the biotech equivalent of writing a prenup that accounts for acts of God.
The Two-Speed FDA Problem
There's an irony buried in all of this. The DOGE-era FDA simultaneously wants to move faster and is losing the people who know how to do that safely.
On one hand, the agency is rolling out new pathways designed to accelerate reviews: the Commissioner's Priority Voucher pilot, a "PreCheck" program for manufacturing, even an AI tool called "Elsa" to assist with scientific reviews. On the other hand, staffing cuts and leadership churn are creating what analysts call a less predictable review process overall.
For non-voucher applications (the vast majority of drugs in the pipeline), the concern is that resources diverted to priority programs will slow everything else down. Expect more late-cycle information requests, more three-month extensions of review deadlines, and more inconsistency across therapeutic divisions. Companies are being advised to treat PDUFA goal dates as targets, not guarantees.
The upcoming user fee reauthorization negotiations for 2028 through 2032 will be critical. Those commitment letters, expected in draft form by fall 2026, will likely try to formalize some of the new programs while adjusting review timelines and communication milestones. But until then, sponsors are navigating without a clear map.
What Happens Next
The FDA has asked Congress to make the Rare Pediatric Disease PRV program permanent, which would eliminate the repeated "will they or won't they" cliffhangers that have plagued the program. That request appeared in the FDA's FY2027 budget proposal, and it has bipartisan appeal. If it happens, expect PRV prices to stabilize, though probably at elevated levels given strong demand.
The Commissioner's Priority Voucher pilot is a different animal. Without clear statutory backing, it's vulnerable to legal challenges that could invalidate decisions made under it. If a court rules that the program exceeded FDA's authority, approvals granted through it could face scrutiny. That's not a theoretical risk; it's the kind of scenario that keeps regulatory lawyers up at night.
For now, the biotech industry finds itself in an uncomfortable position. The incentive that has driven billions of dollars into rare disease research is still functional, but the machinery around it is creaking. Staff are confused about authority. Leaders keep leaving. Legal foundations are shaky for the newest programs.
The golden tickets are still worth a fortune. The question is whether the factory can keep running long enough to honor them.
Deals & M&A
5 min read
Lilly Just Bought a Startup That Wants to Make Viruses Obsolete
Eli Lilly dropped $202 million on a startup with zero human data and a technology that could make viral gene therapy delivery obsolete. The bet makes more sense than you'd think.
